Diffuse large B-cell lymphoma (DLBCL)
Cytolytic T-cell response to the PASD1 cancer testis antigenin patients with diffuse large B-cell lymphoma
... with diffuse large B-cell lymphoma Diffuse large B-cell lymphoma (DLBCL), representing 40% of non-Hodgkin lymphoma (NHL), is heterogeneous with ...
12
Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044
... Abstract Diffuse large B- cell lymphoma (DLBCL) is the most common form of non- Hodgkin’s ...DLBCL cell lines with SM1044 induces autophagy- dependent apoptosis, which is ...
18
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies
... Abstract CNS relapse is reported in 2–5% of diffuse large B- cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk ...
10
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
... with diffuse large B cell lymphoma ...T cell technology has fuelled demand for validated cancer ...T cell (CTL) and a CD4 T-helper (Th) ...
10
Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
... Hodgkin lymphoma among adults, diffuse large B-cell lymphoma (DLBCL), but not in another type of mature aggressive B-cell lymphoma, Burkitt lymphoma ( ...
13
Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type
... Abstract: Diffuse large B cell lymphoma (DLBCL) is a heterogenous disease that has been distinguished into at least two major molecular entities, the germinal center-like B ...
17
Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma.
... www.landesbioscience.com Cell Cycle 1811 Cell Cycle 12:12, 1811–1812; June 15, 2013; © 2013 Landes Bioscience EditoriaLs: CELL CyCLE FEaturEs EditoriaLs: CELL CyCLE FEaturEs Diffuse ...
3
Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort
... of diffuse large B-cell lymphoma (DLBCL) © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution ...
14
CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma
... novo diffuse large B-cell lymphoma; DLBCL(t): diffuse large B-cell lymphoma trans- formed; TCR: T-cell rich B-cell ...
9
Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituximab-MiniCHOP plus Lenalidomide in diffuse large B-Cell lymphoma for patients age 80 years or older.
... with diffuse large B-cell lymphoma (DLBCL) is worse than that of young ...center B-cell–like phenotype. The Lymphoma Study association conducted a multicentric, ...
12
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
... ABSTRACT Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained ...
8
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
... with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study ...in diffuse large B-cell lymphomas treated within randomized trials of the German ...
12
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
... 6 Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN et al. Vitamin D Insufficiency and Prognosis in Non-Hodgkin’s Lymphoma. J Clin Oncol 2010; 28: 4191–4198. 7 Wilcox RA, Ristow K, Habermann TM, ...
12
Gene expression-based risk score in diffuse large B-cell lymphoma.
... develop lymphoma after a long latency[33]. In non-Hodgkin lymphoma, MCL1 expression was signiicantly lower in patients in complete remission than with progressive ...
12
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non- Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
... Introduction B-cell non-Hodgkin lymphoma (NHL) originates from B lymphocytes at various stages of differentiation, from precursor to mature ...with B-cell NHL are treated with ...
15
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
... refractory diffuse large B-cell lymphoma (DLBCL), follicular lym- phoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or ...
12
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
... follicular lymphoma (FL), non-germinal center B-cell (non- GCB) diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and ...
7
Pro-apoptotic effect of doxycycline and hydroxychloroquine on B-cell lymphoma induced by C. burnetii
... inhibits cell growth and promotes apoptosis in tumor cells by activating caspase-3 and ...squamous cell carcinoma and in two- thirds of MALT lymphoma associated with Chlamydia psittaci ...of ...
3
Long non-coding RNAs as molecular signatures for canine B-Cell lymphoma characterization
... Background: Diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) are the most common B-cell lymphomas (BCL) in ...
12
Increased activation of PI3 kinase-δ predisposes to B cell lymphoma.
... Furthermore, B cell lymphoma has been reported for several patients not included in these cohort studies - thus further highlighting the risk of B cell lymphoma in patients with ...
17